At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
PF-07258669 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF-07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating PF-07258669 and Placebo for Healthy Participants. Completed, enrolled 29 participants across 1 site.
Detailed Summary
This study will be the first time PF-07258669 is administered to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of PF-07258669 following administration of single oral doses to healthy adult participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartMar 2021
Primary CompletionAug 2021
TodayJul 2026
First PostedNov 16, 2020
Enrollment StartMar 16, 2021
Primary CompletionAug 25, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.6 years ago
Interventions
PF-07258669drug
PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
Placebodrug
Matching placebo will be prepared as an oral solution and/or suspension given in each cohort